Drug
Erdafitinib clinical trials
Also written JNJ-42756493 and Balversa.
- studies test it
- 36
- open now
- 2
- in phase 3
- 1
- first study started
- 2012
Keep track of what changes. Save the erdafitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 17
- Phase 2
- 19
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 17
Janssen Research & Development, LLC (16) · National Cancer Institute (NCI) (7) · Janssen Pharmaceutical K.K. (2) · University Health Network, Toronto (2) · Memorial Sloan Kettering Cancer Center (1) · Multiple Myeloma Research Consortium (1) · Vanderbilt-Ingram Cancer Center (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
Often tested with
Tested in the same studies.
Palbociclib (4) · Nivolumab (3) · Pembrolizumab (3) · Afatinib (2) · Crizotinib (2) · Dabrafenib (2) · Larotrectinib (2) · Pertuzumab (2)
Studies
Open first, then newest update. How each study uses erdafitinib is read from its arms, and is right about nine times in ten.
Testing it · 36
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationEarly Phase 1Brigham and Women's HospitalNCT06204614Written as Erdafitinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Erdafitinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Erdafitinib
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03210714Written as Erdafitinib
- Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05859334Written as Erdafitinib
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06351371Written as Erdafitinib
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03390504Written as Erdafitinib
- Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT05316155Written as Erdafitinib Intravesical Delivery System
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruitingPhase 2Janssen Research & Development, LLCNCT02365597Written as Erdafitinib
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04963153Written as Erdafitinib
- A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene AlterationsCompletedPhase 2Janssen Research & Development, LLCNCT04083976Written as Erdafitinib
- Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06308822Written as Erdafitinib
- A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04917809Written as Erdafitinib
- A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingPhase 1Janssen Pharmaceutical K.K.NCT05567185Written as Erdafitinib Intravesical Delivery System
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Erdafitinib
- A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedPhase 2Janssen Research & Development, LLCNCT04172675Written as Erdafitinib
- Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT04754425Written as Erdafitinib
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersCompletedPhase 1Janssen Pharmaceutical K.K.NCT03547037Written as Erdafitinib
- A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedPhase 2Janssen Research & Development, LLCNCT02699606Written as Erdafitinib
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedPhase 1/2Multiple Myeloma Research ConsortiumNCT03732703Written as Erdafitinib, dexamethasone, ixazomib, pomalidomide
See all 36 studies that test erdafitinib →
Given in every arm · 2 — erdafitinib is usual care beside what is tested
- A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerActive, not recruitingPhase 1/2Janssen Research & Development, LLCNCT03473743Written as Erdafitinib
- Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnPhase 2National Cancer Institute (NCI)NCT05564416Written as Erdafitinib
Codes
What other systems call erdafitinib · ClinicalTrials.gg INT000393
- MeSH (NLM) C000604580erdafitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 890E37NHMVERDAFITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2123125One source FDA
- Wikidata Q27077213erdafitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103273ErdafitinibOne source FDA
- DrugBank DB12147One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604580 | erdafitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 890E37NHMV | ERDAFITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2123125 | — | One source FDA |
| Wikidata | Q27077213 | erdafitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103273 | Erdafitinib | One source FDA |
| DrugBank | DB12147 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.